Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3882MR)

This product GTTS-WQ3882MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3882MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ151MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ8641MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ4509MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ614MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ515MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ7358MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ5407MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ1135MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW